US drugs giant Pfizer has sealed a deal to buy Botox-maker Allergan for $160bn (£106bn) in what is the biggest pharmaceuticals deal in history. Read the full story

An interview with Richard Brudnick, Senior VP, Corporate Development, Biogen

De-risking has evolved from literature searches to the cultivation of many wide-ranging relationships throughout the life sciences strata, according to Richard Brudnick, Senior VP, Corporate Development at Biogen. In a recent interview, Brudnick outlined key strategies to accessing innovation and “de-risking” risk through collaboration. Read the full story

Bayer HealthCare has entered into an exclusive license agreement with Isis Pharmaceuticals on ISIS-FXIRx Read the full story

4D Molecular Therapeutics announced a collaboration and license agreement with Roche to discover and develop optimized next-generation AAV vectors Read the full story

Celgene and Quanticel Pharmaceuticals announced a definitive share purchase agreement under which Celgene will acquire Quanticel Read the full story

Innate Pharma has signed a co-development and commercialization agreement with AstraZeneca Read the full story

Celgene has entered into a strategic collaboration with MedImmune to develop and commercialize an anti-PD-L1 inhibitor, MEDI4736, for hematologic malignancies Read the full story

Teva Pharmaceutical announced a proposal to acquire all of the outstanding shares of Mylan in a transaction valued at $40 billion Read the full story

Curadev Pharma has entered into a research collaboration and license agreement with Roche for development and commercialization of IDO1 and TDO inhibitors Read the full story

TetraLogic and Merck will collaborate on a Phase 1 study Read the full story